Market Place
Sourcing Support
All News #Library
Biotech
Abcellera To Present ABCL635 Phase 1 Clinical Data In Q1 2026
20 Apr 2026 //
PHARMIWEB
Abcellera Reports Full Year 2025 Business Results
24 Feb 2026 //
BUSINESSWIRE
AbCellera Launches Phase 2 ABCL635 Trial for Menopause Symptoms
12 Jan 2026 //
BUSINESSWIRE
Abcellera Appoints Dr. Stephen Quake To Its Board Of Directors
10 Nov 2025 //
BUSINESS WIRE
Abcellera To Present At Investor Conferences In Nov-Dec 2025
07 Oct 2025 //
PHARMIWEB
Dr. Sarah Noonberg Becomes AbCellera`s Chief Medical Officer
10 Sep 2025 //
PHARMAWEB
AbCellera Initiates Phase 1 Trial for ABCL575
27 Aug 2025 //
PHARMAWEB
AbCellera authorized by Health Canada for Ph1 Trial of ABCL635
14 May 2025 //
BUSINESSWIRE
AbCellera Presents Data on ABCL575 at 2025 SID Meeting
09 May 2025 //
BUSINESSWIRE
AbCellera to Report Q1 2025 Financial Results on May 8, 2025
03 Apr 2025 //
BUSINESSWIRE
AbCellera presents In Vivo Data on PSMA x CD3 T-Cell Engagers
25 Mar 2025 //
BUSINESSWIRE
AbCellera, AbbVie Partner to Develop Novel Oncology T-Cell Engagers
13 Jan 2025 //
BUSINESSWIRE
AbCellera Presents Data on T-Cell Engager Platform at SITC 2024
07 Nov 2024 //
BUSINESSWIRE
AbCellera To Present At November 2024 Investor Conferences
22 Oct 2024 //
BUSINESSWIRE
AbCellera Announces T-cell Engager Presentation At SITC Meeting
04 Oct 2024 //
BUSINESSWIRE
AbCellera, VCs Launch New Biotech Companies Collaboration
01 May 2024 //
BUSINESSWIRE
Vancouver-based antibody therapy firm AbCellera to lay off 10% of workforce
29 Nov 2023 //
CBC
AbCellera Announces Collaboration with Incyte for Antibodies in Oncology
13 Sep 2023 //
BUSINESSWIRE
AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
13 Sep 2023 //
CONTRACT PHARMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.